Valuation: Cartesian Therapeutics, Inc.

Market Cap 30Cr 26Cr 24Cr 22Cr 42Cr 2.91TCr 42Cr 288.18Cr 112.06Cr 1.46TCr 114.05Cr 111.58Cr 4.83TCr P/E 2026 *
-3.36x
P/E 2027 * -2.42x
Enterprise Value 16Cr 14Cr 13Cr 12Cr 23Cr 1.56TCr 23Cr 154.41Cr 60Cr 782.59Cr 61Cr 60Cr 2.59TCr EV / Sales 2026 *
429x
EV / Sales 2027 * 56.3x
Free-Float
47.87%
Yield 2026 *
-
Yield 2027 * -
1 day+2.39%
1 week+11.76%
Current month+31.54%
1 month+30.20%
3 months+59.07%
6 months+35.89%
Current year+42.30%
1 week 9
Extreme 9
10.87
1 month 7.27
Extreme 7.27
10.87
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11.38
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap.
06/01/26 Sell

Chief Technology Officer

3,573 0.0137%
06/01/26 Sell

Chief Executive Officer

23,766 0.0914%
06/01/26 Sell

Chief Financial Officer

10,591 0.0407%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+11.76%-8.80% - 30Cr
-4.31%-2.14%+65.79%+103.90% 7.21TCr
-4.19%+1.05%+46.47%+85.53% 6.59TCr
-2.81%+23.55%+7.71%-4.93% 2.93TCr
-1.20%-3.27%-3.27%+465.98% 2.75TCr
-4.71%+7.67%+47.63%+18.25% 2.67TCr
-1.81%+0.38%+34.14%-18.33% 2.01TCr
+5.36%-1.67%+270.18%+415.10% 1.82TCr
-2.79%+0.48%+12.09%+562.03% 1.64TCr
+0.45%+3.96%+43.51%+150.07% 1.34TCr
Average -1.37%+9.05%+51.54%+197.51% 2.9TCr
Weighted average by Cap. -2.78%+8.78%+53.83%+154.38%

Financials

2026 *2027 *
Net sales 4L 3L 3L 3L 5L 3.63Cr 5L 35.98L 13.99L 1.82Cr 14.24L 13.93L 6.03Cr 2L 2L 2L 2L 3L 2.39Cr 3L 23.72L 9L 1.2Cr 9L 9L 3.98Cr
Net income -8.74Cr -7.49Cr -7.01Cr -6.41Cr -12Cr -837.29Cr -12Cr -83Cr -32Cr -420.43Cr -33Cr -32Cr -1.39TCr -14Cr -12Cr -11Cr -10Cr -20Cr -1.37TCr -20Cr -135.59Cr -53Cr -687.17Cr -54Cr -52Cr -2.27TCr
Net Debt -14Cr -12Cr -11Cr -10Cr -20Cr -1.35TCr -20Cr -133.77Cr -52Cr -677.94Cr -53Cr -52Cr -2.24TCr -29Cr -25Cr -23Cr -21Cr -40Cr -2.77TCr -40Cr -274.84Cr -106.87Cr -1.39TCr -108.77Cr -106.42Cr -4.61TCr
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
24/26/24 $10.26 +2.19% 76,312
21/26/21 $10.04 -1.86% 1,63,914
20/26/20 $10.23 -2.48% 1,34,750
19/26/19 $10.49 +14.02% 4,82,468
18/26/18 $9.200 +0.22% 1,38,352
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.04USD
Average target price
34.57USD
Spread / Average Target
+244.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNAC Stock